{"id":8932,"date":"2020-03-18T17:38:01","date_gmt":"2020-03-19T01:38:01","guid":{"rendered":"http:\/\/www.drugpolicy.ca\/?p=8932"},"modified":"2021-11-07T07:13:33","modified_gmt":"2021-11-07T15:13:33","slug":"covid-19-guidance-for-clinicians-opioid-treatment-programs","status":"publish","type":"post","link":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/","title":{"rendered":"COVID-19 Guidance for Clinicians &#038; Opioid Treatment Programs"},"content":{"rendered":"\n<iframe loading=\"lazy\" class=\"scribd_iframe_embed\" title=\"YaleADM CoronavirusGuidance Clinicians and OTPs 031620\" src=\"https:\/\/www.scribd.com\/embeds\/452278768\/content?start_page=1&amp;view_mode=scroll&amp;access_key=key-kZopdTuIL1iqq1GFowF2\" data-auto-height=\"false\" data-aspect-ratio=\"0.7735849056603774\" scrolling=\"no\" id=\"doc_51852\" width=\"100%\" height=\"600\" frameborder=\"0\"><\/iframe>\n\n\n\n<div style=\"height:15px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<div class=\"wp-block-button aligncenter\"><a class=\"wp-block-button__link has-background\" href=\"http:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/YaleADM_CoronavirusGuidance_Clinicians-and-OTPs_031620.pdf\" style=\"background-color:#c42127\" target=\"_blank\" rel=\"noreferrer noopener\">Download PDF<\/a><\/div>\n\n\n\n<div style=\"height:10px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"has-text-align-center wp-block-paragraph\"><strong>Click <a href=\"https:\/\/drugpolicy.ca\/resources\/covid-19-harm-reduction-resources\/\" target=\"_blank\" rel=\"noreferrer noopener\">HERE<\/a> for more resources<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><p style=\"margin-top:30px\">Guidance from the Yale Program in Addiction Medicine<\/p><\/p>\n\n\n\n<div class=\"widget signup-widget mb-5\">\r\n<p class=\"lead\"><strong>\u00cates-vous pr\u00eat(e) \u00e0 aider ?<\/strong><\/p>\r\n<p>Soutenez des politiques sur les drogues bas\u00e9es sur la justice sociale, la compassion et les preuves. Inscrivez-vous \u00e0 notre newsletter pour obtenir des mises \u00e0 jour et d\u00e9couvrez comment vous pouvez agir avec nous.<\/p>\r\n<!-- form.123formbuilder.com script begins here --><script type=\"text\/javascript\" defer=\"defer\" src=\"https:\/\/form.123formbuilder.com\/embed\/6415583.js\" data-role=\"form\" data-default-width=\"650px\"><\/script><!-- form.123formbuilder.com script ends here -->\r\n<\/div>\r\n\n\n\n<ul class=\"wp-block-social-links aligncenter is-style-default is-layout-flex wp-block-social-links-is-layout-flex\"><li class=\"wp-social-link wp-social-link-twitter  wp-block-social-link\"><a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/www.twitter.com\/candrugpolicy\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M22.23,5.924c-0.736,0.326-1.527,0.547-2.357,0.646c0.847-0.508,1.498-1.312,1.804-2.27 c-0.793,0.47-1.671,0.812-2.606,0.996C18.324,4.498,17.257,4,16.077,4c-2.266,0-4.103,1.837-4.103,4.103 c0,0.322,0.036,0.635,0.106,0.935C8.67,8.867,5.647,7.234,3.623,4.751C3.27,5.357,3.067,6.062,3.067,6.814 c0,1.424,0.724,2.679,1.825,3.415c-0.673-0.021-1.305-0.206-1.859-0.513c0,0.017,0,0.034,0,0.052c0,1.988,1.414,3.647,3.292,4.023 c-0.344,0.094-0.707,0.144-1.081,0.144c-0.264,0-0.521-0.026-0.772-0.074c0.522,1.63,2.038,2.816,3.833,2.85 c-1.404,1.1-3.174,1.756-5.096,1.756c-0.331,0-0.658-0.019-0.979-0.057c1.816,1.164,3.973,1.843,6.29,1.843 c7.547,0,11.675-6.252,11.675-11.675c0-0.178-0.004-0.355-0.012-0.531C20.985,7.47,21.68,6.747,22.23,5.924z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Twitter<\/span><\/a><\/li>\n\n<li class=\"wp-social-link wp-social-link-facebook  wp-block-social-link\"><a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/www.facebook.com\/candrugpolicy\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M12 2C6.5 2 2 6.5 2 12c0 5 3.7 9.1 8.4 9.9v-7H7.9V12h2.5V9.8c0-2.5 1.5-3.9 3.8-3.9 1.1 0 2.2.2 2.2.2v2.5h-1.3c-1.2 0-1.6.8-1.6 1.6V12h2.8l-.4 2.9h-2.3v7C18.3 21.1 22 17 22 12c0-5.5-4.5-10-10-10z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Facebook<\/span><\/a><\/li>\n\n<li class=\"wp-social-link wp-social-link-instagram  wp-block-social-link\"><a rel=\"noopener nofollow\" target=\"_blank\" href=\"https:\/\/www.instagram.com\/candrugpolicy\" class=\"wp-block-social-link-anchor\"><svg width=\"24\" height=\"24\" viewBox=\"0 0 24 24\" version=\"1.1\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\"><path d=\"M12,4.622c2.403,0,2.688,0.009,3.637,0.052c0.877,0.04,1.354,0.187,1.671,0.31c0.42,0.163,0.72,0.358,1.035,0.673 c0.315,0.315,0.51,0.615,0.673,1.035c0.123,0.317,0.27,0.794,0.31,1.671c0.043,0.949,0.052,1.234,0.052,3.637 s-0.009,2.688-0.052,3.637c-0.04,0.877-0.187,1.354-0.31,1.671c-0.163,0.42-0.358,0.72-0.673,1.035 c-0.315,0.315-0.615,0.51-1.035,0.673c-0.317,0.123-0.794,0.27-1.671,0.31c-0.949,0.043-1.233,0.052-3.637,0.052 s-2.688-0.009-3.637-0.052c-0.877-0.04-1.354-0.187-1.671-0.31c-0.42-0.163-0.72-0.358-1.035-0.673 c-0.315-0.315-0.51-0.615-0.673-1.035c-0.123-0.317-0.27-0.794-0.31-1.671C4.631,14.688,4.622,14.403,4.622,12 s0.009-2.688,0.052-3.637c0.04-0.877,0.187-1.354,0.31-1.671c0.163-0.42,0.358-0.72,0.673-1.035 c0.315-0.315,0.615-0.51,1.035-0.673c0.317-0.123,0.794-0.27,1.671-0.31C9.312,4.631,9.597,4.622,12,4.622 M12,3 C9.556,3,9.249,3.01,8.289,3.054C7.331,3.098,6.677,3.25,6.105,3.472C5.513,3.702,5.011,4.01,4.511,4.511 c-0.5,0.5-0.808,1.002-1.038,1.594C3.25,6.677,3.098,7.331,3.054,8.289C3.01,9.249,3,9.556,3,12c0,2.444,0.01,2.751,0.054,3.711 c0.044,0.958,0.196,1.612,0.418,2.185c0.23,0.592,0.538,1.094,1.038,1.594c0.5,0.5,1.002,0.808,1.594,1.038 c0.572,0.222,1.227,0.375,2.185,0.418C9.249,20.99,9.556,21,12,21s2.751-0.01,3.711-0.054c0.958-0.044,1.612-0.196,2.185-0.418 c0.592-0.23,1.094-0.538,1.594-1.038c0.5-0.5,0.808-1.002,1.038-1.594c0.222-0.572,0.375-1.227,0.418-2.185 C20.99,14.751,21,14.444,21,12s-0.01-2.751-0.054-3.711c-0.044-0.958-0.196-1.612-0.418-2.185c-0.23-0.592-0.538-1.094-1.038-1.594 c-0.5-0.5-1.002-0.808-1.594-1.038c-0.572-0.222-1.227-0.375-2.185-0.418C14.751,3.01,14.444,3,12,3L12,3z M12,7.378 c-2.552,0-4.622,2.069-4.622,4.622S9.448,16.622,12,16.622s4.622-2.069,4.622-4.622S14.552,7.378,12,7.378z M12,15 c-1.657,0-3-1.343-3-3s1.343-3,3-3s3,1.343,3,3S13.657,15,12,15z M16.804,6.116c-0.596,0-1.08,0.484-1.08,1.08 s0.484,1.08,1.08,1.08c0.596,0,1.08-0.484,1.08-1.08S17.401,6.116,16.804,6.116z\"><\/path><\/svg><span class=\"wp-block-social-link-label screen-reader-text\">Instagram<\/span><\/a><\/li><\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Guidance from the Yale Program in Addiction Medicine<\/p>\n","protected":false},"author":38,"featured_media":8939,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_crdt_document":"","footnotes":""},"categories":[1119],"tags":[1124],"class_list":["post-8932","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-covid","tag-safe-supply-oat-and-ioat"],"acf":[],"mb":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>COVID-19 Guidance for Clinicians &amp; Opioid Treatment Programs - Canadian Drug Policy Coalition<\/title>\n<meta name=\"description\" content=\"Guidance from the Yale Program in Addiction Medicine\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"COVID-19 Guidance for Clinicians &amp; Opioid Treatment Programs - Canadian Drug Policy Coalition\" \/>\n<meta property=\"og:description\" content=\"Guidance from the Yale Program in Addiction Medicine\" \/>\n<meta property=\"og:url\" content=\"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/\" \/>\n<meta property=\"og:site_name\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta property=\"article:published_time\" content=\"2020-03-19T01:38:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-07T15:13:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-18-at-6.37.21-PM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"912\" \/>\n\t<meta property=\"og:image:height\" content=\"610\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Canadian Drug Policy Coalition\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Canadian Drug Policy Coalition\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/\"},\"author\":{\"name\":\"Canadian Drug Policy Coalition\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/c32110f234bdb1f5d978710b6b406a30\"},\"headline\":\"COVID-19 Guidance for Clinicians &#038; Opioid Treatment Programs\",\"datePublished\":\"2020-03-19T01:38:01+00:00\",\"dateModified\":\"2021-11-07T15:13:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/\"},\"wordCount\":22,\"publisher\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-18-at-6.37.21-PM.png\",\"keywords\":[\"safe supply OAT and iOAT\"],\"articleSection\":[\"covid\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/\",\"name\":\"COVID-19 Guidance for Clinicians & Opioid Treatment Programs - Canadian Drug Policy Coalition\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-18-at-6.37.21-PM.png\",\"datePublished\":\"2020-03-19T01:38:01+00:00\",\"dateModified\":\"2021-11-07T15:13:33+00:00\",\"description\":\"Guidance from the Yale Program in Addiction Medicine\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-18-at-6.37.21-PM.png\",\"contentUrl\":\"https:\\\/\\\/new.drugpolicy.ca\\\/wp-content\\\/uploads\\\/2020\\\/03\\\/Screen-Shot-2020-03-18-at-6.37.21-PM.png\",\"width\":912,\"height\":610},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/covid-19-guidance-for-clinicians-opioid-treatment-programs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"COVID-19 Guidance for Clinicians &#038; Opioid Treatment Programs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\",\"name\":\"Canadian Drug Policy Coalition\",\"description\":\"Change policy. Save lives.\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#organization\",\"name\":\"Canadian Drug Policy Coalition\",\"url\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"contentUrl\":\"https:\\\/\\\/drugpolicy.ca\\\/wp-content\\\/uploads\\\/2019\\\/04\\\/CDPC-logo-white-on-red-150-dpi.jpg\",\"width\":332,\"height\":333,\"caption\":\"Canadian Drug Policy Coalition\"},\"image\":{\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.drugpolicy.ca\\\/fr\\\/#\\\/schema\\\/person\\\/c32110f234bdb1f5d978710b6b406a30\",\"name\":\"Canadian Drug Policy Coalition\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g\",\"caption\":\"Canadian Drug Policy Coalition\"},\"description\":\"Advocating for public health- and human rights-based drug policy grounded in evidence, compassion, and social justice\",\"url\":\"https:\\\/\\\/new.drugpolicy.ca\\\/fr\\\/author\\\/canadian-drug-policy-coalition\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"COVID-19 Guidance for Clinicians & Opioid Treatment Programs - Canadian Drug Policy Coalition","description":"Guidance from the Yale Program in Addiction Medicine","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/","og_locale":"fr_FR","og_type":"article","og_title":"COVID-19 Guidance for Clinicians & Opioid Treatment Programs - Canadian Drug Policy Coalition","og_description":"Guidance from the Yale Program in Addiction Medicine","og_url":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/","og_site_name":"Canadian Drug Policy Coalition","article_published_time":"2020-03-19T01:38:01+00:00","article_modified_time":"2021-11-07T15:13:33+00:00","og_image":[{"width":912,"height":610,"url":"https:\/\/www.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-18-at-6.37.21-PM.png","type":"image\/png"}],"author":"Canadian Drug Policy Coalition","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Canadian Drug Policy Coalition","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/#article","isPartOf":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/"},"author":{"name":"Canadian Drug Policy Coalition","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/person\/c32110f234bdb1f5d978710b6b406a30"},"headline":"COVID-19 Guidance for Clinicians &#038; Opioid Treatment Programs","datePublished":"2020-03-19T01:38:01+00:00","dateModified":"2021-11-07T15:13:33+00:00","mainEntityOfPage":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/"},"wordCount":22,"publisher":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization"},"image":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-18-at-6.37.21-PM.png","keywords":["safe supply OAT and iOAT"],"articleSection":["covid"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/","url":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/","name":"COVID-19 Guidance for Clinicians & Opioid Treatment Programs - Canadian Drug Policy Coalition","isPartOf":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/#primaryimage"},"image":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/#primaryimage"},"thumbnailUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-18-at-6.37.21-PM.png","datePublished":"2020-03-19T01:38:01+00:00","dateModified":"2021-11-07T15:13:33+00:00","description":"Guidance from the Yale Program in Addiction Medicine","breadcrumb":{"@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/#primaryimage","url":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-18-at-6.37.21-PM.png","contentUrl":"https:\/\/new.drugpolicy.ca\/wp-content\/uploads\/2020\/03\/Screen-Shot-2020-03-18-at-6.37.21-PM.png","width":912,"height":610},{"@type":"BreadcrumbList","@id":"https:\/\/new.drugpolicy.ca\/fr\/covid-19-guidance-for-clinicians-opioid-treatment-programs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.drugpolicy.ca\/fr\/"},{"@type":"ListItem","position":2,"name":"COVID-19 Guidance for Clinicians &#038; Opioid Treatment Programs"}]},{"@type":"WebSite","@id":"https:\/\/www.drugpolicy.ca\/fr\/#website","url":"https:\/\/www.drugpolicy.ca\/fr\/","name":"Canadian Drug Policy Coalition","description":"Change policy. Save lives.","publisher":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.drugpolicy.ca\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.drugpolicy.ca\/fr\/#organization","name":"Canadian Drug Policy Coalition","url":"https:\/\/www.drugpolicy.ca\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","contentUrl":"https:\/\/drugpolicy.ca\/wp-content\/uploads\/2019\/04\/CDPC-logo-white-on-red-150-dpi.jpg","width":332,"height":333,"caption":"Canadian Drug Policy Coalition"},"image":{"@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.drugpolicy.ca\/fr\/#\/schema\/person\/c32110f234bdb1f5d978710b6b406a30","name":"Canadian Drug Policy Coalition","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9f79e2b1a0ccc3ac68e2c3b14806186aa5e053de86cb3e0ee34e1971e8c4a3f7?s=96&d=mm&r=g","caption":"Canadian Drug Policy Coalition"},"description":"Advocating for public health- and human rights-based drug policy grounded in evidence, compassion, and social justice","url":"https:\/\/new.drugpolicy.ca\/fr\/author\/canadian-drug-policy-coalition\/"}]}},"mfb_rest_fields":["title","yoast_head","yoast_head_json"],"_links":{"self":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/8932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/users\/38"}],"replies":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/comments?post=8932"}],"version-history":[{"count":7,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/8932\/revisions"}],"predecessor-version":[{"id":16969,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/posts\/8932\/revisions\/16969"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media\/8939"}],"wp:attachment":[{"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/media?parent=8932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/categories?post=8932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/new.drugpolicy.ca\/fr\/wp-json\/wp\/v2\/tags?post=8932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}